EGFR and neoplasm: Our data clearly shows that tumor clones with EGFR ectodomain mutations are not sensitive to EGFR targeting, but don't seem to be stimulated by the antibody and therefore may have a lesser growth advantage than RAS mutant subclones during EGFR-directed therapeutic pressure.